OncoZenge AB Statistics

Total Valuation

OncoZenge AB has a market cap or net worth of SEK 77.02 million. The enterprise value is 72.93 million.

Market Cap	77.02M
Enterprise Value	72.93M

Important Dates

The next estimated earnings date is Wednesday, February 18, 2026.

Earnings Date	Feb 18, 2026
Ex-Dividend Date	n/a

Share Statistics

OncoZenge AB has 12.65 million shares outstanding. The number of shares has increased by 1.57% in one year.

Current Share Class	12.65M
Shares Outstanding	12.65M
Shares Change (YoY)	+1.57%
Shares Change (QoQ)	+5.97%
Owned by Insiders (%)	33.69%
Owned by Institutions (%)	11.21%
Float	5.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	27.68
PB Ratio	8.28
P/TBV Ratio	31.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.52
EV / Sales	26.21
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.28, with a Debt / Equity ratio of 0.81.

Current Ratio	4.28
Quick Ratio	4.13
Debt / Equity	0.81
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-569.40

Financial Efficiency

Return on equity (ROE) is -78.64% and return on invested capital (ROIC) is -36.49%.

Return on Equity (ROE)	-78.64%
Return on Assets (ROA)	-31.88%
Return on Invested Capital (ROIC)	-36.49%
Return on Capital Employed (ROCE)	-50.83%
Revenue Per Employee	2.78M
Profits Per Employee	-8.56M
Employee Count	1
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.46% in the last 52 weeks. The beta is 1.44, so OncoZenge AB's price volatility has been higher than the market average.

Beta (5Y)	1.44
52-Week Price Change	+4.46%
50-Day Moving Average	5.98
200-Day Moving Average	5.89
Relative Strength Index (RSI)	41.92
Average Volume (20 Days)	33,471

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OncoZenge AB had revenue of SEK 2.78 million and -8.56 million in losses. Loss per share was -0.72.

Revenue	2.78M
Gross Profit	2.78M
Operating Income	-8.54M
Pretax Income	-8.56M
Net Income	-8.56M
EBITDA	n/a
EBIT	-8.54M
Loss Per Share	-0.72

Full Income Statement

Balance Sheet

The company has 11.59 million in cash and 7.50 million in debt, with a net cash position of 4.09 million or 0.32 per share.

Cash & Cash Equivalents	11.59M
Total Debt	7.50M
Net Cash	4.09M
Net Cash Per Share	0.32
Equity (Book Value)	9.30M
Book Value Per Share	0.74
Working Capital	9.95M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-7.78M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-306.90%
Pretax Margin	-307.40%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OncoZenge AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.57%
Shareholder Yield	-1.57%
Earnings Yield	-11.11%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

OncoZenge AB has an Altman Z-Score of -2.35 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.35
Piotroski F-Score	1